SIV Vaccine Success

A cytomegalovirus-based vaccine eliminated simian immunodeficiency virus from rhesus macaques, raising hopes of a similarly effective HIV vaccine.

By | September 13, 2013

SIV virionNIH, SRIRAM SUBRAMANIAMA vaccine has eliminated simian immunodeficiency virus (SIV) in some rhesus macaques, which remained uninfected for as long as three years post-treatment, according to a study published in Nature yesterday (September 12).

Previously, researchers had shown that about half of rhesus macaques given the vaccine were protected from SIV infection. The new study showed that monkeys given the vaccine and then infected with SIV showed no signs of the virus in their systems even though it had originally taken hold.

“The virus got in, it infected some cells, moved about in various parts of the body, but it was subsequently cleared, so that by two or three years later the monkeys looked like normal monkeys,” study coauthor Louis Picker from Oregon Health and Science University told Gizmodo.

The vaccine contains a cytomegalovirus that expresses SIV proteins, stimulating the immune system to recognize and attempt to eliminate the virus. The researchers now hope to determine whether the vaccine can eliminate SIV if administered after an SIV infection has taken hold, BBC News reported. The researchers hope to launch human trials within two years.

“It’s always tough to claim eradication—there could always be a cell which we didn't analyze that has the virus in it,” Picker told BBC. “But for the most part, with very stringent criteria . . . there was no virus left in the body of these monkeys.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Sequencing Reveals Genomic Diversity of the Human Brain
  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech